Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction

JAMA

Volumn 277, Issue 2, 1997, Pages 115-121

  Soumerai, Stephen B ^a   McLaughlin, Thomas J ^a   Spiegelman, Donna ^b   Hertzmark, Ellen ^b   Thibault, George ^c   Goldman, Lee ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE;

ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG UTILIZATION; ELDERLY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0031025108     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.2.115     Document Type: Article

References (44)

1. Kennedy HL, Rosenson RS. Physician use of beta-adrenergic biocking therapy: a changing perspective. J Am Coll Cardiol. 1995;26:547-552.
2. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myoeardial infarction. N Engl J Med. 1988;319:152-157.
3. Antman EM, Lau J, Kupelnick B, Hosteller F, Chalmers TC. A comparison of results of metaanalyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA. 1992;268:240-248.
4. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chaimers TC. Cumulative metaanalysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-254.
5. The Norwegian Multicenter Study. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
6. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714.
7. ACC/AHA Task Force. Guidelines for the early management of patients with acute myocardial in-farction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardio-vascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol. 1990;16:249-292.
8. Jansen RWMM, Gurwitz JH. Controversies surrounding the use of β-blockers in older patients with cardiovascular disease. Drugs Aging. 1994;4: 175-183.
9. Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ. 1991;302:91-92.
10. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol. 1995;26:1432-1436.
11. Chassin MR, Brook RH, Park RE, et al. Variations in the use of medical and surgical practices by the Medicare population. N Engl J Med. 1986;314: 285-290.
12. Wennberg JE. Dealing with medical practice variations: a proposal for action. Health Aff (Millwood). Summer 1984;3:6-32.
13. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
14. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris C, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
15. Epstein AM. Acute myocardial infarction in the Medicare population: process of care and clinical outcomes. JAMA. 1992;268:2530-2536.
16. Lohr KN. Use of insurance claims data in measuring quality of care. Int J Tech Assess Health Care. 1990;6:263-271.
17. Roos LL, Roos NP, Fisher E, et al. Strengths and Weaknesses of Health Insurance Data Systems for Assessing Outcomes: Paper Prepared for the Study to Design a Strategy for Quality Review and Assurance in Medicare. Washington, DC: Institute of Medicine, National Academy of Sciences; May 1989.
18. Wennberg JE, Roos NP, Sola L, et al. Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA. 1987;257:933-936.
19. Sacks H, Chalmers TC, Smith H. Randomized versus historical controls for clinical trials. Am J Med. 1982;72:233-240.
20. Temple R. Problems in the use of large data sets to assess effectiveness. Int J Tech Assess Health Care. 1990;6:211-219.
21. Ray WA, Griffin MR, Baugh DK. Mortality following hip fracture before and after implementation of the prospective payment system. Arch Intern Med. 1990;150:2109-2114.
22. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology.Am J Epidemiol. 1989;129: 837-849.
23. Soumerai SB, Avorn J, Ross-Degnan D, Gort-maker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
24. Pashos CL, Normand SLT, Garfinkle JB, et al. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol. 1994;23:1023-1030.
25. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health. 1992;82:243-248.
26. Iezzoni LI, Burnside S, Sickles L, et al. Coding of acute myocardial infarction: clinical and policy implications. Ann Intern Med. 1988;109:745-751.
27. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. JAMA. 1989; 261:253-257.
28. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med. 1991;325:221-225.
29. Wenneker MB, Weissman JS, Epstein AM. The association of payer with utilization of cardiac procedures in Massachusetts. JAMA. 1990;264:1255-1260.
30. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
31. Harrell FE, Pollock BG, Lee KL. Graphical methods for the analysis of survival data. In: Proceedings of the 12th Annual SAS Users Group International Conference. Gary, NC: SAS Institute Inc; 1988:1107-1115.
32. Harrell FE, Lee KL. Verifying assumptions of the Cox proportional hazards model. In: Proceedings of the 11th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 1987:823-828
33. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923-936.
34. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification in the propensity score. J Am Stat Assoc. 1984;79:516-524.
35. Ayanian J, Hauptman PJ, Guadagnoli E, et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-1142.
36. Lamas GA, Pfeffer MA, Hamm P, et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-247.
37. Kennedy HL, Brooks MM, Barker AM, et al, for the CAST Investigators. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1994;74:674-680.
38. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national consensus guidelines for drug treatment of suspected acute myocardial infarction in community hospitals: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799-805.
39. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med. 1994; 9:599-605.
40. Dahlof C, Dimenas E, Kendall M, Wiklund I. Quality of life in cardiovascular diseases: emphasis on β-blocker treatment. Circulation. 1991;84(suppl VI):VI-108-VI-118.
41. Burns JF. β-Blockers, dyslipidemia, and coronary artery disease: a reassessment. Arch Intern Med. 1993:153:2085-2092.
42. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995:273:1509-1514.
43. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
44. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med. 1990;89:630-638.